HUP0200774A2 - Amino-piridin és amino-kinolin származékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és intermedierjeik - Google Patents
Amino-piridin és amino-kinolin származékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és intermedierjeik Download PDFInfo
- Publication number
- HUP0200774A2 HUP0200774A2 HU0200774A HUP0200774A HUP0200774A2 HU P0200774 A2 HUP0200774 A2 HU P0200774A2 HU 0200774 A HU0200774 A HU 0200774A HU P0200774 A HUP0200774 A HU P0200774A HU P0200774 A2 HUP0200774 A2 HU P0200774A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- straight
- carbon atoms
- compounds
- general formula
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- 230000008569 process Effects 0.000 title claims description 3
- 150000005010 aminoquinolines Chemical class 0.000 title abstract description 4
- 150000003927 aminopyridines Chemical class 0.000 title abstract 3
- 239000000543 intermediate Substances 0.000 title description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 92
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 54
- -1 methylenedioxy Chemical group 0.000 claims abstract description 41
- 150000003839 salts Chemical class 0.000 claims abstract description 35
- 239000012453 solvate Substances 0.000 claims abstract description 34
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 30
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 28
- 125000005843 halogen group Chemical group 0.000 claims abstract description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 20
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 16
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 16
- 125000002541 furyl group Chemical group 0.000 claims abstract description 14
- 125000001544 thienyl group Chemical group 0.000 claims abstract description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 5
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims abstract description 5
- 230000003288 anthiarrhythmic effect Effects 0.000 claims abstract description 4
- 230000001088 anti-asthma Effects 0.000 claims abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 4
- 239000003416 antiarrhythmic agent Substances 0.000 claims abstract description 4
- 239000000924 antiasthmatic agent Substances 0.000 claims abstract description 4
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 57
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 43
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 34
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 21
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 19
- 229960005305 adenosine Drugs 0.000 claims description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 125000004434 sulfur atom Chemical group 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 230000007062 hydrolysis Effects 0.000 claims description 11
- 238000006460 hydrolysis reaction Methods 0.000 claims description 11
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 6
- 208000010412 Glaucoma Diseases 0.000 claims description 6
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 6
- 210000003169 central nervous system Anatomy 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- FFHQNQNMELQOEF-UHFFFAOYSA-N SSR161421 Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=NC2=CC=CC=C2C(NCC=2C=CC=CC=2)=C1C#N FFHQNQNMELQOEF-UHFFFAOYSA-N 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 210000002216 heart Anatomy 0.000 claims description 5
- 210000003630 histaminocyte Anatomy 0.000 claims description 5
- 230000001681 protective effect Effects 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- SPDQSSIORISFDN-UHFFFAOYSA-N n-[4-(benzylamino)-3-cyanoquinolin-2-yl]-3-methylbenzamide Chemical compound CC1=CC=CC(C(=O)NC=2C(=C(NCC=3C=CC=CC=3)C3=CC=CC=C3N=2)C#N)=C1 SPDQSSIORISFDN-UHFFFAOYSA-N 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 3
- 208000026872 Addison Disease Diseases 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 208000000059 Dyspnea Diseases 0.000 claims description 3
- 206010013975 Dyspnoeas Diseases 0.000 claims description 3
- 206010014561 Emphysema Diseases 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 206010021143 Hypoxia Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 208000012659 Joint disease Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims description 3
- 241000208225 Rhus Species 0.000 claims description 3
- 235000014220 Rhus chinensis Nutrition 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 3
- 208000024780 Urticaria Diseases 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 230000000172 allergic effect Effects 0.000 claims description 3
- 230000001430 anti-depressive effect Effects 0.000 claims description 3
- 230000002253 anti-ischaemic effect Effects 0.000 claims description 3
- 230000000648 anti-parkinson Effects 0.000 claims description 3
- 239000000935 antidepressant agent Substances 0.000 claims description 3
- 229940005513 antidepressants Drugs 0.000 claims description 3
- 239000000939 antiparkinson agent Substances 0.000 claims description 3
- 206010003119 arrhythmia Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 208000007451 chronic bronchitis Diseases 0.000 claims description 3
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 3
- 230000016396 cytokine production Effects 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 210000003979 eosinophil Anatomy 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 230000007954 hypoxia Effects 0.000 claims description 3
- 210000004969 inflammatory cell Anatomy 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 230000004410 intraocular pressure Effects 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 3
- 230000005012 migration Effects 0.000 claims description 3
- 238000013508 migration Methods 0.000 claims description 3
- 230000003680 myocardial damage Effects 0.000 claims description 3
- RPAVWYIOZRGQBK-UHFFFAOYSA-N n-[3-cyano-4-(thiophen-2-ylmethylamino)quinolin-2-yl]-1,3-benzodioxole-5-carboxamide Chemical compound C=1C=C2OCOC2=CC=1C(=O)NC(C=1C#N)=NC2=CC=CC=C2C=1NCC1=CC=CS1 RPAVWYIOZRGQBK-UHFFFAOYSA-N 0.000 claims description 3
- ASXCZWNWTKMPIU-UHFFFAOYSA-N n-[4-(benzylamino)-3-cyanoquinolin-2-yl]-1,3-benzodioxole-5-carboxamide Chemical compound C=1C=C2OCOC2=CC=1C(=O)NC(C=1C#N)=NC2=CC=CC=C2C=1NCC1=CC=CC=C1 ASXCZWNWTKMPIU-UHFFFAOYSA-N 0.000 claims description 3
- KZHOXMICZFBDDR-UHFFFAOYSA-N n-[4-(benzylamino)-3-cyanoquinolin-2-yl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=C(NCC=3C=CC=CC=3)C3=CC=CC=C3N=2)C#N)=C1 KZHOXMICZFBDDR-UHFFFAOYSA-N 0.000 claims description 3
- ZFBYATAXTNWUKQ-UHFFFAOYSA-N n-[4-(benzylamino)-3-cyanoquinolin-2-yl]thiophene-2-carboxamide Chemical compound C=1C=CSC=1C(=O)NC(C=1C#N)=NC2=CC=CC=C2C=1NCC1=CC=CC=C1 ZFBYATAXTNWUKQ-UHFFFAOYSA-N 0.000 claims description 3
- 230000007658 neurological function Effects 0.000 claims description 3
- 210000000440 neutrophil Anatomy 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 230000010410 reperfusion Effects 0.000 claims description 3
- 201000004193 respiratory failure Diseases 0.000 claims description 3
- 210000002345 respiratory system Anatomy 0.000 claims description 3
- 206010039083 rhinitis Diseases 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 229910001854 alkali hydroxide Inorganic materials 0.000 claims description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 2
- XSWSGVCWMTYDHC-UHFFFAOYSA-N n-[3-cyano-4-(furan-2-ylmethylamino)quinolin-2-yl]furan-2-carboxamide Chemical compound C=1C=COC=1C(=O)NC(C=1C#N)=NC2=CC=CC=C2C=1NCC1=CC=CO1 XSWSGVCWMTYDHC-UHFFFAOYSA-N 0.000 claims description 2
- JAPZLARAKVKDGB-UHFFFAOYSA-N n-[3-cyano-4-(furan-2-ylmethylamino)quinolin-2-yl]thiophene-3-carboxamide Chemical compound C1=CSC=C1C(=O)NC(C=1C#N)=NC2=CC=CC=C2C=1NCC1=CC=CO1 JAPZLARAKVKDGB-UHFFFAOYSA-N 0.000 claims description 2
- LASGMIKSCBSSAT-UHFFFAOYSA-N n-[3-cyano-4-(thiophen-2-ylmethylamino)quinolin-2-yl]-4-methoxybenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=NC2=CC=CC=C2C(NCC=2SC=CC=2)=C1C#N LASGMIKSCBSSAT-UHFFFAOYSA-N 0.000 claims description 2
- RBVFCHLFDTUSCP-UHFFFAOYSA-N n-[3-cyano-4-(thiophen-2-ylmethylamino)quinolin-2-yl]thiophene-3-carboxamide Chemical compound C1=CSC=C1C(=O)NC(C=1C#N)=NC2=CC=CC=C2C=1NCC1=CC=CS1 RBVFCHLFDTUSCP-UHFFFAOYSA-N 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims 9
- 230000008602 contraction Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 229940126601 medicinal product Drugs 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 210000003437 trachea Anatomy 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 230000003907 kidney function Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 238000012360 testing method Methods 0.000 abstract description 10
- 239000002580 adenosine A3 receptor antagonist Substances 0.000 abstract description 3
- 229910052760 oxygen Inorganic materials 0.000 abstract description 2
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 230000003266 anti-allergic effect Effects 0.000 abstract 1
- 230000002456 anti-arthritic effect Effects 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 230000002682 anti-psoriatic effect Effects 0.000 abstract 1
- 230000003356 anti-rheumatic effect Effects 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 239000003435 antirheumatic agent Substances 0.000 abstract 1
- 208000021822 hypotensive Diseases 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 description 31
- 108020003175 receptors Proteins 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 21
- 238000002844 melting Methods 0.000 description 16
- 230000008018 melting Effects 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 10
- 239000012528 membrane Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- XMNBZTMWILHWPS-UHFFFAOYSA-N 2-amino-4-(benzylamino)quinoline-3-carbonitrile Chemical compound N#CC=1C(N)=NC2=CC=CC=C2C=1NCC1=CC=CC=C1 XMNBZTMWILHWPS-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 108050000203 Adenosine receptors Proteins 0.000 description 6
- 102000009346 Adenosine receptors Human genes 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000002287 radioligand Substances 0.000 description 5
- RRHVNLMYGHTZJC-UHFFFAOYSA-N 2-amino-4-chloroquinoline-3-carbonitrile Chemical compound C1=CC=C2C(Cl)=C(C#N)C(N)=NC2=C1 RRHVNLMYGHTZJC-UHFFFAOYSA-N 0.000 description 4
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 4
- 102000055025 Adenosine deaminases Human genes 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003365 glass fiber Substances 0.000 description 4
- 238000001525 receptor binding assay Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- LELCQSVSHYQGMI-UHFFFAOYSA-N 2-amino-4-(thiophen-2-ylmethylamino)quinoline-3-carbonitrile Chemical compound N#CC=1C(N)=NC2=CC=CC=C2C=1NCC1=CC=CS1 LELCQSVSHYQGMI-UHFFFAOYSA-N 0.000 description 3
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 3
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 108060000200 adenylate cyclase Proteins 0.000 description 3
- 102000030621 adenylate cyclase Human genes 0.000 description 3
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- RIRGCFBBHQEQQH-SSFGXONLSA-N (-)-n6-(2-phenylisopropyl)adenosine Chemical compound C([C@@H](C)NC=1C=2N=CN(C=2N=CN=1)[C@H]1[C@@H]([C@H](O)[C@@H](CO)O1)O)C1=CC=CC=C1 RIRGCFBBHQEQQH-SSFGXONLSA-N 0.000 description 2
- XSMYYYQVWPZWIZ-IDTAVKCVSA-N (2r,3r,4s,5r)-2-[2-chloro-6-(cyclopentylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Cl)=NC(NC3CCCC3)=C2N=C1 XSMYYYQVWPZWIZ-IDTAVKCVSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- FFBDFADSZUINTG-UHFFFAOYSA-N DPCPX Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1CCCC1 FFBDFADSZUINTG-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000699673 Mesocricetus auratus Species 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000002178 crystalline material Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- XWFWXDCLZBTWKP-UHFFFAOYSA-N n-[4-(benzylamino)-3-cyanoquinolin-2-yl]-3-methyl-n-(3-methylbenzoyl)benzamide Chemical compound CC1=CC=CC(C(=O)N(C(=O)C=2C=C(C)C=CC=2)C=2C(=C(NCC=3C=CC=CC=3)C3=CC=CC=C3N=2)C#N)=C1 XWFWXDCLZBTWKP-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- QTWBEVAYYDZLQL-UHFFFAOYSA-N thiophene-3-carbonyl chloride Chemical compound ClC(=O)C=1C=CSC=1 QTWBEVAYYDZLQL-UHFFFAOYSA-N 0.000 description 2
- LOGOEBMHHXYBID-WBKNRDRNSA-N (2s,3s,4r,5r)-5-[6-[(4-amino-3-iodanylphenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=C([125I])C(N)=CC=3)=C2N=C1 LOGOEBMHHXYBID-WBKNRDRNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical group C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- ZRSGZIMDIHBXIN-UHFFFAOYSA-N 1,3-benzodioxole-5-carbonyl chloride Chemical compound ClC(=O)C1=CC=C2OCOC2=C1 ZRSGZIMDIHBXIN-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical class C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- MCLFCZKVPRPRDS-UHFFFAOYSA-N 2-amino-4-(furan-2-ylmethylamino)quinoline-3-carbonitrile Chemical compound N#CC=1C(N)=NC2=CC=CC=C2C=1NCC1=CC=CO1 MCLFCZKVPRPRDS-UHFFFAOYSA-N 0.000 description 1
- USKBIWBLJHCVOP-UHFFFAOYSA-N 2-amino-4-oxo-1h-quinoline-3-carbonitrile Chemical compound C1=CC=C2C(O)=C(C#N)C(N)=NC2=C1 USKBIWBLJHCVOP-UHFFFAOYSA-N 0.000 description 1
- OFTKFKYVSBNYEC-UHFFFAOYSA-N 2-furoyl chloride Chemical compound ClC(=O)C1=CC=CO1 OFTKFKYVSBNYEC-UHFFFAOYSA-N 0.000 description 1
- RUQIUASLAXJZIE-UHFFFAOYSA-N 3-methoxybenzoyl chloride Chemical compound COC1=CC=CC(C(Cl)=O)=C1 RUQIUASLAXJZIE-UHFFFAOYSA-N 0.000 description 1
- YHOYYHYBFSYOSQ-UHFFFAOYSA-N 3-methylbenzoyl chloride Chemical compound CC1=CC=CC(C(Cl)=O)=C1 YHOYYHYBFSYOSQ-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- 108010041368 Adenosine A2 Receptors Proteins 0.000 description 1
- 102000000506 Adenosine A2 Receptors Human genes 0.000 description 1
- PAOANWZGLPPROA-RQXXJAGISA-N CGS-21680 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(O)=O)=CC=3)=NC(N)=C2N=C1 PAOANWZGLPPROA-RQXXJAGISA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 101000783756 Homo sapiens Adenosine receptor A2b Proteins 0.000 description 1
- 101000783645 Homo sapiens Adenosine receptor A3 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 102000011420 Phospholipase D Human genes 0.000 description 1
- 108090000553 Phospholipase D Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000037411 cognitive enhancing Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000001091 dromotropic effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 102000055126 human ADORA2B Human genes 0.000 description 1
- 102000046278 human ADORA3 Human genes 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036540 impulse transmission Effects 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- DLUOHEDCUDTLJS-UHFFFAOYSA-N n-(1,3-benzodioxole-5-carbonyl)-n-[3-cyano-4-(thiophen-2-ylmethylamino)quinolin-2-yl]-1,3-benzodioxole-5-carboxamide Chemical compound C=1C=C2OCOC2=CC=1C(=O)N(C(=O)C=1C=C2OCOC2=CC=1)C(C=1C#N)=NC2=CC=CC=C2C=1NCC1=CC=CS1 DLUOHEDCUDTLJS-UHFFFAOYSA-N 0.000 description 1
- UGDIJRQCGCKOGJ-UHFFFAOYSA-N n-(1,3-benzodioxole-5-carbonyl)-n-[4-(benzylamino)-3-cyanoquinolin-2-yl]-1,3-benzodioxole-5-carboxamide Chemical compound C=1C=C2OCOC2=CC=1C(=O)N(C(=O)C=1C=C2OCOC2=CC=1)C(C=1C#N)=NC2=CC=CC=C2C=1NCC1=CC=CC=C1 UGDIJRQCGCKOGJ-UHFFFAOYSA-N 0.000 description 1
- ZKGFAYGUDHGILX-UHFFFAOYSA-N n-[3-cyano-4-(furan-2-ylmethylamino)quinolin-2-yl]-n-(furan-2-carbonyl)furan-2-carboxamide Chemical compound C=1C=COC=1C(=O)N(C=1C(=C(NCC=2OC=CC=2)C2=CC=CC=C2N=1)C#N)C(=O)C1=CC=CO1 ZKGFAYGUDHGILX-UHFFFAOYSA-N 0.000 description 1
- GAQJWTKIANSWPL-UHFFFAOYSA-N n-[3-cyano-4-(furan-2-ylmethylamino)quinolin-2-yl]-n-(thiophene-3-carbonyl)thiophene-3-carboxamide Chemical compound C1=CSC=C1C(=O)N(C=1C(=C(NCC=2OC=CC=2)C2=CC=CC=C2N=1)C#N)C(=O)C=1C=CSC=1 GAQJWTKIANSWPL-UHFFFAOYSA-N 0.000 description 1
- ADWFCGTVTMWDGH-UHFFFAOYSA-N n-[3-cyano-4-(thiophen-2-ylmethylamino)quinolin-2-yl]-4-methoxy-n-(4-methoxybenzoyl)benzamide Chemical compound C1=CC(OC)=CC=C1C(=O)N(C=1C(=C(NCC=2SC=CC=2)C2=CC=CC=C2N=1)C#N)C(=O)C1=CC=C(OC)C=C1 ADWFCGTVTMWDGH-UHFFFAOYSA-N 0.000 description 1
- BAHXFWSCBQCJLT-UHFFFAOYSA-N n-[3-cyano-4-(thiophen-2-ylmethylamino)quinolin-2-yl]-n-(thiophene-3-carbonyl)thiophene-3-carboxamide Chemical compound C1=CSC=C1C(=O)N(C=1C(=C(NCC=2SC=CC=2)C2=CC=CC=C2N=1)C#N)C(=O)C=1C=CSC=1 BAHXFWSCBQCJLT-UHFFFAOYSA-N 0.000 description 1
- DRGPHPHWEMETAE-UHFFFAOYSA-N n-[4-(benzylamino)-3-cyanoquinolin-2-yl]-3-methoxy-n-(3-methoxybenzoyl)benzamide Chemical compound COC1=CC=CC(C(=O)N(C(=O)C=2C=C(OC)C=CC=2)C=2C(=C(NCC=3C=CC=CC=3)C3=CC=CC=C3N=2)C#N)=C1 DRGPHPHWEMETAE-UHFFFAOYSA-N 0.000 description 1
- FNKBZPRGOKISLM-UHFFFAOYSA-N n-[4-(benzylamino)-3-cyanoquinolin-2-yl]-4-methoxy-n-(4-methoxybenzoyl)benzamide Chemical compound C1=CC(OC)=CC=C1C(=O)N(C=1C(=C(NCC=2C=CC=CC=2)C2=CC=CC=C2N=1)C#N)C(=O)C1=CC=C(OC)C=C1 FNKBZPRGOKISLM-UHFFFAOYSA-N 0.000 description 1
- XBJASQBMEPDRST-UHFFFAOYSA-N n-[4-(benzylamino)-3-cyanoquinolin-2-yl]-n-(thiophene-2-carbonyl)thiophene-2-carboxamide Chemical compound C=1C=CSC=1C(=O)N(C=1C(=C(NCC=2C=CC=CC=2)C2=CC=CC=C2N=1)C#N)C(=O)C1=CC=CS1 XBJASQBMEPDRST-UHFFFAOYSA-N 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000003395 phenylethylamino group Chemical group [H]N(*)C([H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- HDOUGSFASVGDCS-UHFFFAOYSA-N pyridin-3-ylmethanamine Chemical compound NCC1=CC=CN=C1 HDOUGSFASVGDCS-UHFFFAOYSA-N 0.000 description 1
- TXQWFIVRZNOPCK-UHFFFAOYSA-N pyridin-4-ylmethanamine Chemical compound NCC1=CC=NC=C1 TXQWFIVRZNOPCK-UHFFFAOYSA-N 0.000 description 1
- ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 150000008634 thiazolopyrimidines Chemical class 0.000 description 1
- FKKJJPMGAWGYPN-UHFFFAOYSA-N thiophen-2-ylmethanamine Chemical compound NCC1=CC=CS1 FKKJJPMGAWGYPN-UHFFFAOYSA-N 0.000 description 1
- QIQITDHWZYEEPA-UHFFFAOYSA-N thiophene-2-carbonyl chloride Chemical compound ClC(=O)C1=CC=CS1 QIQITDHWZYEEPA-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000009284 tracheal contraction Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (30)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0200774A HUP0200774A2 (hu) | 2002-03-01 | 2002-03-01 | Amino-piridin és amino-kinolin származékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és intermedierjeik |
| TW091110975A TWI328581B (en) | 2002-03-01 | 2002-05-24 | New compounds |
| SK1414-2003A SK14142003A3 (sk) | 2001-05-31 | 2002-05-29 | Aminochinolínové a aminopyridínové deriváty a ich použitie ako adenozínových A3 ligandov |
| EA200301317A EA006854B1 (ru) | 2001-05-31 | 2002-05-29 | Производные аминохинолина и его применение в качестве лигандов аденозина a |
| YUP-950/03A RS95003A (sr) | 2001-05-31 | 2002-05-29 | Derivati aminohinolina i aminopiridina i njihova upotreba kao liganada adenozinskih a3 receptora |
| MXPA03010870A MXPA03010870A (es) | 2001-05-31 | 2002-05-29 | Derivados de aminoquinolina y aminopiridina y su uso como ligandos de a3 de adenosina. |
| KR1020037015646A KR100745307B1 (ko) | 2001-05-31 | 2002-05-29 | 아미노퀴놀린 유도체 및 아데노신 ａ３ 리간드로서의 이의 용도 |
| PCT/HU2002/000048 WO2002096879A1 (en) | 2001-05-31 | 2002-05-29 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands |
| RU2003137836/04A RU2278112C2 (ru) | 2001-05-31 | 2002-05-29 | Производные аминохинолина и аминопиридина и их применение в качестве лигандов аденозина a3 |
| BR0209719-2A BR0209719A (pt) | 2001-05-31 | 2002-05-29 | Derivados de aminoquinolina e aminopiridina e seu uso como ligandos de adenosina a3 |
| MEP-186/08A MEP18608A (en) | 2001-05-31 | 2002-05-29 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands |
| AU2002304358A AU2002304358B2 (en) | 2001-05-31 | 2002-05-29 | Aminoquinoline and aminopyridine derivatives and their use as adenosine A3 ligands |
| NZ529966A NZ529966A (en) | 2001-05-31 | 2002-05-29 | Aminoquinoline and aminopyridine derivatives and their use as adenosine A3 ligands |
| CZ20033510A CZ20033510A3 (cs) | 2001-05-31 | 2002-05-29 | Aminochinolinové a aminopyridinové deriváty a jejich použití jako adenosinových A3 ligandů |
| EP02732985A EP1390349B1 (en) | 2001-05-31 | 2002-05-29 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands |
| CNB02810840XA CN1257160C (zh) | 2001-05-31 | 2002-05-29 | 氨基喹啉衍生物和它们的作为腺苷a3配体的应用 |
| IL15885402A IL158854A0 (en) | 2001-05-31 | 2002-05-29 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands |
| CA2448561A CA2448561C (en) | 2001-05-31 | 2002-05-29 | Aminoquinoline derivatives and their use as adenosine a3 ligands |
| EEP200300574A EE05304B1 (et) | 2001-05-31 | 2002-05-29 | Aminokinoliini derivaadid, meetod nende valmistamiseks, neid sisaldavad ravimkoostised ja nende kasutamine adenosiini A3-retseptori ligandidena |
| HRP20031091AA HRP20031091B1 (en) | 2001-05-31 | 2002-05-29 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands |
| JP2003500059A JP4409935B2 (ja) | 2001-05-31 | 2002-05-29 | アミノキノリンおよびアミノピリジン誘導体およびそのアデノシンａ３リガンドとしての使用 |
| US10/478,721 US6969723B2 (en) | 2001-05-31 | 2002-05-29 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands |
| PL02366516A PL366516A1 (en) | 2001-05-31 | 2002-05-29 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands |
| ARP020102036A AR036074A1 (es) | 2001-05-31 | 2002-05-31 | Derivados de aminoquinolina, las composiciones farmaceuticas que los contienen, el uso de los mismos para la preparacion de una composicion farmaceutica, un procedimiento para su preparacion y los intermediarios empleados en dicho procedimiento de preparacion |
| TNPCT/HU2002/000048A TNSN03117A1 (en) | 2001-05-31 | 2003-07-08 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands |
| MA27388A MA26236A1 (fr) | 2001-05-31 | 2003-11-10 | Derives d'aminoquinoline et d'aminopyrridine et leur utilisation comme ligands d'adenosine a3 |
| IS7052A IS2773B (is) | 2001-05-31 | 2003-11-26 | Amínókínólínafleiður og notkun þeirra sem adenósín A3-bindlar |
| NO20035300A NO327710B1 (no) | 2001-05-31 | 2003-11-28 | Aminokinolinderivater og deres anvendelse som adenosin A<N>3</N>-ligander |
| CO03107462A CO5550457A2 (es) | 2001-05-31 | 2003-12-05 | Derivados de aminoquinolina |
| BG108477A BG108477A (bg) | 2001-05-31 | 2003-12-19 | Аминохинолинови и аминопиридинови производни и тяхното използване като аденозин-а3-лиганди |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0200774A HUP0200774A2 (hu) | 2002-03-01 | 2002-03-01 | Amino-piridin és amino-kinolin származékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és intermedierjeik |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0200774D0 HUP0200774D0 (enExample) | 2002-05-29 |
| HUP0200774A2 true HUP0200774A2 (hu) | 2005-10-28 |
Family
ID=89575035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0200774A HUP0200774A2 (hu) | 2001-05-31 | 2002-03-01 | Amino-piridin és amino-kinolin származékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és intermedierjeik |
Country Status (2)
| Country | Link |
|---|---|
| HU (1) | HUP0200774A2 (enExample) |
| TW (1) | TWI328581B (enExample) |
-
2002
- 2002-03-01 HU HU0200774A patent/HUP0200774A2/hu unknown
- 2002-05-24 TW TW091110975A patent/TWI328581B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0200774D0 (enExample) | 2002-05-29 |
| TWI328581B (en) | 2010-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7709489B2 (en) | Imidazoquinoline derivatives as adenosine A3 receptor ligands | |
| JP2011042653A (ja) | アデノシン受容体リガンドとして有用なトリアゾロ−キノリン誘導体 | |
| JP4409935B2 (ja) | アミノキノリンおよびアミノピリジン誘導体およびそのアデノシンａ３リガンドとしての使用 | |
| JP2007500689A (ja) | アミノキノリン誘導体およびアデノシンａ３リガンドとしてのそれらの使用 | |
| KR100725298B1 (ko) | 이미다조퀴놀린 유도체 | |
| HUP0400302A2 (hu) | Amino-kinolin és aminopiridinszármazékok és alkalmazásuk A3 adenozine-ligandként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0102279A2 (hu) | A3 antagonista amino-kinolin-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0302440A2 (hu) | Amino-kinolin származékok, eljárás előállításukra és ezeket hatóanyagként tartalmazó gyógyszerkészítmények | |
| KR20070020335A (ko) | 아미노퀴놀린 유도체 및 아데노신 ａ３ 리간드로서의 이의용도 | |
| HUP0402424A2 (hu) | Imidazo-kinolin-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HK1077819B (en) | Imidazoquinoline derivatives as adenosine a3 receptor ligands | |
| TWI328581B (en) | New compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |